Gilead Sciences, Inc. (GILD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Gilead Sciences presented a strong growth outlook at the Morgan Stanley Global Healthcare Conference, highlighting its successful six-year diversification strategy, robust balance sheet, and disciplined expense management, with no major patent expiries until late 2033. The company is strategically ensuring the durability of its HIV franchise beyond 2033 via a pipeline of lenacapavir-based long-acting therapies, including the successful Yeztugo launch and a once-a-year prevention candidate by 2028. Significant progress was also noted in oncology, with strong Q2 clinical execution for Trodelvy and imido-cel, and an early-stage inflammation pipeline is being cultivated for longer-term growth, underscoring Gilead's focus on broad portfolio expansion and commercial execution.

Analysis

Gilead Sciences' management presented a highly confident growth narrative, underpinned by a diversification strategy executed over the past six years. The company's financial position is framed as robust, citing a strong balance sheet, significant cash flows, and a shift towards disciplined expense management after a period of purposeful investment. A key pillar of the investment thesis is the durability of the HIV franchise, with no major patent expiries until late 2033 for Biktarvy. Management is actively de-risking this future cliff by building a portfolio of eight lenacapavir-based programs, diversifying within the HIV segment itself. The commercial strategy is evident in the 35% year-over-year Q2 growth of Descovy, which is expanding the PrEP market ahead of the pivotal Yeztugo launch. For Yeztugo, key near-term catalysts include the October 1st effective J-code to ease physician prescribing and stated coverage goals of 75% within six months and 90% within twelve. Beyond HIV, the oncology portfolio has more than doubled, highlighted by strong Q2 clinical results for Trodelvy in first-line triple-negative breast cancer and anito-cel in multiple myeloma, with further readouts expected in the next 12-18 months. The company is also positioning its CAR-T therapies for the community setting, where 80% of multiple myeloma is treated. The inflammation pipeline is positioned as a longer-term growth driver for the post-2030 period. Management addressed policy headwinds by noting its relatively lower exposure to potential tariffs due to its US-domiciled IP (80%) and outlining mitigating factors for Medicaid risks, such as state-level assistance programs.

Key Decisions for Investors

• Investors should closely monitor the execution of the Yeztugo launch, specifically tracking payer coverage milestones and the impact of the October 1st J-code on prescription uptake, as this is the first major test of the lenacapavir-based strategy to ensure HIV franchise durability beyond 2033.
• The oncology pipeline represents a significant near-term catalyst; focus should be on clinical trial readouts for Trodelvy and cell therapy programs over the next 12-18 months, as positive data could accelerate the company's valuation shift towards a diversified biopharma leader.
• While management appears confident in navigating policy risks, it is prudent to monitor developments in Medicaid reimbursement and final formulary decisions by major PBMs, as these factors remain the primary external headwinds to the company's near-term growth trajectory.
• Consider the company's strategic move of its CAR-T franchise into community settings as a critical execution point to watch, given that successfully capturing this market is essential for the potential launch of anito-cel in multiple myeloma, where 80% of treatment occurs.